Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Fred Loe, MD, and the History of Trachoma

Fred Loe, MD, and the History of Trachoma SPECIAL ARTICLE Robert M. Feibel, MD rachoma has been one of the most blinding diseases in the history of ophthalmology. From its initial description in antiquity until the late 1930s, no specific treatment or effective cure had been known, and the only expedient had been to destroy the dis- T eased tissue containing the infectious agent, rendering the disease inactive. Virtually all medical, mechanical, and surgical treatments were unsatisfactory, with cure rates of approxi- mately 20%. Therapy for trachoma had barely advanced from the measures used by the ancient Egyptian, Greek, and Roman physicians. All prior therapies became obsolete in 1938 when Fred Loe, MD, working on an American Indian reservation, introduced sulfanilamide as a treatment of trachoma, achieving a 90% cure rate. One of the most unusual aspects of Loe’s career was that he had no formal training in ophthalmology and was completely self-taught as an ophthalmologist. Arch Ophthalmol. 2011;129(4):503-508 In the history of ophthalmology, 2 dis- “land of the blind.” The French, British, and eases predominate for their long history, other armies that invaded Egypt experi- their wide-ranging effect on blindness, and enced severe trachoma and other infec- their continuing importance in the con- tious subtypes of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Fred Loe, MD, and the History of Trachoma

Feibel, Robert M.
JAMA Ophthalmology , Volume 129 (4) – Apr 1, 2011
Download PDF
6 pages

Loading next page...
 
/lp/american-medical-association/fred-loe-md-and-the-history-of-trachoma-2567N2Unym

References (22)

Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archophthalmol.2011.64
pmid
21482877
Publisher site
See Article on Publisher Site

Abstract

SPECIAL ARTICLE Robert M. Feibel, MD rachoma has been one of the most blinding diseases in the history of ophthalmology. From its initial description in antiquity until the late 1930s, no specific treatment or effective cure had been known, and the only expedient had been to destroy the dis- T eased tissue containing the infectious agent, rendering the disease inactive. Virtually all medical, mechanical, and surgical treatments were unsatisfactory, with cure rates of approxi- mately 20%. Therapy for trachoma had barely advanced from the measures used by the ancient Egyptian, Greek, and Roman physicians. All prior therapies became obsolete in 1938 when Fred Loe, MD, working on an American Indian reservation, introduced sulfanilamide as a treatment of trachoma, achieving a 90% cure rate. One of the most unusual aspects of Loe’s career was that he had no formal training in ophthalmology and was completely self-taught as an ophthalmologist. Arch Ophthalmol. 2011;129(4):503-508 In the history of ophthalmology, 2 dis- “land of the blind.” The French, British, and eases predominate for their long history, other armies that invaded Egypt experi- their wide-ranging effect on blindness, and enced severe trachoma and other infec- their continuing importance in the con- tious subtypes of

Journal

JAMA Ophthalmology – American Medical Association

Published: Apr 1, 2011

There are no references for this article.